|View printer-friendly version|
|November 27, 2002 4:27 p.m.|
|Teva Announces Approval of Pergolide Mesylate Tablets|
Jerusalem, Israel, November 27, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has issued final approval for the company's ANDA for Pergolide Mesylate Tablets. This is the first generic approval for Pergolide Mesylate Tablets. The FDA has advised Teva that its application was the first to contain a patent challenge for this product and therefore Teva is entitled to 180 days of marketing exclusivity. Shipments are expected to begin immediately.